Scarica l'app Stockscreener
6.90
2.07%
0.14
Dopo l'orario di chiusura:
6.88
-0.02
-0.29%
Precedente Chiudi:
$6.76
Aprire:
$6.61
Volume 24 ore:
347.38K
Relative Volume:
0.86
Capitalizzazione di mercato:
$351.05M
Reddito:
$228.37M
Utile/perdita netta:
$31.11M
Rapporto P/E:
11.30
EPS:
0.6108
Flusso di cassa netto:
$41.73M
1 W Prestazione:
+10.05%
1M Prestazione:
+7.48%
6M Prestazione:
+32.18%
1 anno Prestazione:
+129.24%
Intervallo 1D:
$6.54
$6.99
Intervallo di 1 settimana:
$6.00
$6.99
Portata 52W:
$2.575
$7.68
Puma Biotechnology Inc Stock (PBYI) Company Profile
Nome
Puma Biotechnology Inc
Settore
Industria
Telefono
(424) 248-6500
Indirizzo
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
6.90 | 351.05M | 228.37M | 31.11M | 41.73M | 0.6108 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Underperform |
| 2019-10-08 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-10 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2019-01-17 | Iniziato | Leerink Partners | Mkt Perform |
| 2019-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-11-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-11-02 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Iniziato | Goldman | Sell |
| 2018-05-11 | Reiterato | Stifel | Buy |
| 2017-11-10 | Reiterato | Citigroup | Buy |
| 2017-11-10 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Reiterato | Stifel | Buy |
| 2017-09-11 | Reiterato | Credit Suisse | Outperform |
| 2017-07-10 | Ripresa | Leerink Partners | Outperform |
| 2017-06-06 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Reiterato | RBC Capital Mkts | Sector Perform |
Mostra tutto
Puma Biotechnology Inc Borsa (PBYI) Ultime notizie
Investor Mood: Is Puma Biotechnology Inc undervalued by DCF analysisWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 - BioSpace
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Pharma News: Is Puma Biotechnology Inc a momentum stockAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Recap Report: What is Puma Biotechnology Incs 5 year growth outlook2026 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn
Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially - Investing.com
Earnings call transcript: Puma Biotechnology Inc. reports strong Q4 2025 results - in.investing.com
Vanguard disaggregates holdings; Puma Biotechnology (PBYI) shows 0 shares reported - stocktitan.net
Forecast Cut: Is Puma Biotechnology Inc a momentum stockPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
Rate Hike: Can Puma Biotechnology Inc be the next market leaderPortfolio Update Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Puma Biotechnology stock declines more than 9% in a month: Here's why - msn.com
Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy - MarketBeat
Shorts Report: Is Puma Biotechnology Inc undervalued by DCF analysis2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn
Whats the MACD signal for Puma Biotechnology Inc2026 Market WrapUp & Weekly Setup with ROI Potential - baoquankhu1.vn
Earnings Miss: Can Puma Biotechnology Inc be the next market leaderQuarterly Trade Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - Yahoo Finance
Buy Signal: Is Puma Biotechnology Inc trading at a discount2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Puma Biotechnology Stock Crosses 200-Day Moving Average - National Today
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Published on: 2026-03-12 08:35:52 - baoquankhu1.vn
Puma Biotech (PBYI) Earnings Call Transcript - AOL.com
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen - MarketBeat
PBYI Q4 earnings & sales beat estimates, stock down on weak 2026 view - MSN
Puma Biotechnology, Inc. (PBYI) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Puma Biotech at TD Cowen Conference: Strategic Growth and Financial Discipline - Investing.com Canada
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2025 Earnings Call Transcript - Insider Monkey
PBYI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen - MarketBeat
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - The Globe and Mail
PBYI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Puma Biotechnology Hits New 52-Week High of $7.68, Up 120% - Markets Mojo
Puma Biotechnology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-02-27 - Seeking Alpha
Earnings call transcript: Puma Biotechnology Q4 2025 beats forecasts with strong revenue growth - Investing.com India
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology Q4 Earnings Call Highlights - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Puma Biotechnology Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Puma Biotech: Fourth Quarter Earnings Overview - Bitget
Puma Biotechnology (PBYI) Releases Q4 2025 Earnings: Revenue Beats, EPS Tops Estimates but Cash Falls - Quiver Quantitative
Puma Biotechnology Q4 Earnings Report: What Investors Need to Know - Benzinga
Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Puma Biotechnology Inc expected to post earnings of 23 cents a shareEarnings Preview - TradingView
Analyst Downgrade: Is The Oncology Institute Inc Equity Warrants ROE strong enoughWeekly Trend Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference - BioSpace
Puma Biotechnology Inc Azioni (PBYI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):